| Biomarker ID | 926 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Methylated in PCA: |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | recurrent prostate cancer Vs nonrecurrent cancer |
| Type of Biomarker | Prognostic |
| Cohort | 4 different sub groups of patients with prostate cancer: (i) tumor versus matched normal tissues ((ii) recurrence versus nonrecurrence (iii) clinical versus biochemical recurrence and (iv) systemic recurrence versus local recurrence. 20 patients from each group were taken |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CRIP1, RUNX3, HS3ST2, FLNC, RASGRF2 |